MAP2K7 and B-cell chronic lymphocytic leukemia: Recently, we also reported that CUDC‐907 can be combined with MEK inhibitors to overcome the resistance of CLL cells to these drugs.58 The potential combinations of CUDC‐907 treatments could therefore be numerous.